{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:04:35Z","timestamp":1782601475278,"version":"3.54.5"},"reference-count":251,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.semarthrit.2007.06.002","type":"journal-article","created":{"date-parts":[[2007,8,22]],"date-time":"2007-08-22T11:13:20Z","timestamp":1187781200000},"page":"273-292","source":"Crossref","is-referenced-by-count":63,"title":["Primary Sjogren\u2019s Syndrome: Current and Prospective Therapies"],"prefix":"10.1016","volume":"37","author":[{"given":"Aikaterini","family":"Thanou-Stavraki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2007.06.002_bib1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.semarthrit.2006.08.007","article-title":"The overlap of Sjogren\u2019s syndrome with other systemic autoimmune diseases","volume":"36","author":"Ramos-Casals","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/03009740310004676","article-title":"Estimating the prevalence among Caucasian women of primary Sjogren\u2019s syndrome in two general practices in Birmingham, UK","volume":"33","author":"Bowman","year":"2004","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib3","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"European Study Group on Classification Criteria for Sjogren\u2019s Syndrome","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/ard.2004.025676","article-title":"Primary Sjogren\u2019s syndrome: new clinical and therapeutic concepts","volume":"64","author":"Ramos-Casals","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib5","first-page":"270","article-title":"Primary Sjogren syndrome","volume":"81","author":"Garcia-Carrasco","year":"2002","journal-title":"Medicine"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.md.0000141099.53742.16","article-title":"Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients","volume":"83","author":"Delalande","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/01.md.0000119465.24818.98","article-title":"Cutaneous vasculitis in primary Sjogren syndrome: classification and clinical significance of 52 patients","volume":"83","author":"Ramos-Casals","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00005792-200207000-00004","article-title":"Primary Sjogren syndrome: hematologic patterns of disease expression","volume":"81","author":"Ramos-Casals","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib9","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V","article-title":"Malignant lymphoma in primary Sjogren\u2019s syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren\u2019s Syndrome","volume":"42","author":"Voulgarelis","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","article-title":"Sjogren\u2019s syndrome","volume":"366","author":"Fox","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib11","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/art.10221","article-title":"Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren\u2019s syndrome","volume":"46","author":"Ioannidis","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib12","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0049-0172(00)80016-5","article-title":"Clinical evolution, and morbidity and mortality of primary Sjogren\u2019s syndrome","volume":"29","author":"Skopouli","year":"2000","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib13","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1001\/archinte.164.12.1275","article-title":"Clinical manifestations and early diagnosis of Sjogren syndrome","volume":"164","author":"Kassan","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0896-1549(02)00105-0","article-title":"The evolving treatment of dry eye","volume":"16","author":"Foulks","year":"2003","journal-title":"Ophthalmol Clin North Am"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1600-0668.2006.00429.x","article-title":"The modern office environment desiccates the eyes?","volume":"16","author":"Wolkoff","year":"2006","journal-title":"Indoor Air"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0896-1549(02)00066-4","article-title":"The evolution in therapeutic contact lenses","volume":"16","author":"Shah","year":"2003","journal-title":"Ophthalmol Clin North Am"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib17","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/01.opx.0000171818.01353.8c","article-title":"The effect of two novel lubricant eye drops on tear film lipid layer thickness in subjects with dry eye symptoms","volume":"82","author":"Korb","year":"2005","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib18","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/bjo.86.8.879","article-title":"Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjogren\u2019s syndrome patients","volume":"86","author":"Aragona","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/archopht.117.3.389","article-title":"Punctal occlusion","volume":"117","author":"Cohen","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/01.iop.0000231773.20993.79","article-title":"A permanent and reversible procedure to block tear drainage for the treatment of dry eye","volume":"22","author":"Demartelaere","year":"2006","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.ico.0000164783.10667.a4","article-title":"Atelocollagen punctal occlusion in dry eye patients","volume":"25","author":"Miyata","year":"2006","journal-title":"Cornea"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib22","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0002-9394(00)00822-9","article-title":"The effect of punctal occlusion on tear production, tear clearance, and ocular surface sensation in normal subjects","volume":"131","author":"Yen","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib23","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/bjo.2003.026211","article-title":"Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease","volume":"88","author":"Noble","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ajo.2004.08.040","article-title":"The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study","volume":"139","author":"Kojima","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib25","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/bjo.2004.044347","article-title":"Autologous serum eye drops for ocular surface disorders","volume":"88","author":"Geerling","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib26","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1167\/iovs.05-0876","article-title":"Corneal epitheliotrophic capacity of three different blood-derived preperations","volume":"47","author":"Liu","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1006\/clim.2001.5128","article-title":"Use of muscarinic agonists in the treatment of Sjogren\u2019s syndrome","volume":"101","author":"Fox","year":"2001","journal-title":"Clin Immunol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib28","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/978-1-4615-5359-5_139","article-title":"Oral pilocarpine for symptomatic relief of dry mouth and dry eyes in patients with Sjogrens syndrome","volume":"438","author":"Papas","year":"1998","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib29","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archinte.159.2.174","article-title":"Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms inpatients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial","volume":"159","author":"Vivino","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib30","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/ard.2002.003889","article-title":"Oral pilocarpine for the treatment of ocular symptoms in patients with Sjogren\u2019s syndrome: a randomised 12 week controlled study","volume":"62","author":"Tsifetaki","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib31","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/art.510","article-title":"A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren\u2019s syndrome patients with xerostomia and keratoconjunctivitis sicca","volume":"46","author":"Petrone","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2007.06.002_bib32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ajo.2004.02.010","article-title":"Therapeutic effect of cevimeline on dry eye in patients with Sjogren\u2019s syndrome: a randomized, double-blind clinical study","volume":"138","author":"Ono","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7696(03)31001-0","article-title":"Role of mucins in the function of the corneal and conjunctival epithelia","volume":"231","author":"Gipson","year":"2003","journal-title":"Int Rev Cytol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000076887","article-title":"Diquafosol elicits increases in net Cl[minud] transport through P2Y2 receptor stimulation in rabbit conjunctiva","volume":"36","author":"Murakami","year":"2004","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib35","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/01.ico.0000133993.14768.a9","article-title":"Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye","volume":"23","author":"Tauber","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib36","first-page":"S713","article-title":"Phase II dose ranging efficacy trial of INS365 ophthalmic solution, a P2Y2 agonist, in patients with dry eye","volume":"42","author":"Foulks","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib37","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003226-200211000-00018","article-title":"Characterization of human ocular mucin secretion mediated by 15(S)-HETE","volume":"21","author":"Jumblatt","year":"2002","journal-title":"Cornea"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib38","first-page":"1818","article-title":"Human corneal and conjunctival epithelia express MUC1 mucin","volume":"36","author":"Inatomi","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib39","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/00003226-200107000-00015","article-title":"The eicosanoid, 15-(S)-HETE, stimulates secretion of mucin-like glycoprotein by the corneal epithelium","volume":"20","author":"Jackson","year":"2001","journal-title":"Cornea"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib40","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1089\/10807680260218515","article-title":"Corneal protection by the ocular mucin secretagogue 15(S)-HETE in a rabbit model of desiccation-induced corneal defect","volume":"18","author":"Gamache","year":"2002","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib41","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/01.ico.0000126436.25751.fb","article-title":"Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model","volume":"23","author":"Urashima","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib42","article-title":"Multicenter, Randomized, Double-Masked, Dose\u2013Response, Placebo\u2013Controlled, Parallel\u2013Group Study of the safety and efficacy of rebamipide (OPC-12759) sterile ophthalmic suspension in the treatment of dry eye","volume":"46","author":"Donshik","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib43","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1006\/exer.1997.0366","article-title":"Gefarnate stimulates secretion of mucin-like glycoproteins by corneal epithelium in vitro and protects corneal epithelium from desiccation in vivo","volume":"65","author":"Nakamura","year":"1997","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib44","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00003226-200204000-00011","article-title":"Effect of gefarnate on the ocular surface in squirrel monkeys","volume":"21","author":"Toshida","year":"2002","journal-title":"Cornea"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00003226-199307000-00007","article-title":"Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca","volume":"12","author":"Laibovitz","year":"1993","journal-title":"Cornea"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib46","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1755-3768.1994.tb02792.x","article-title":"Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogren\u2019s syndrome","volume":"72","author":"Gunduz","year":"1994","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib47","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease CsA Phase III Study Group","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib48","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/archopht.118.11.1489","article-title":"Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes","volume":"118","author":"Kunert","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib49","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archopht.120.3.330","article-title":"Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine","volume":"120","author":"Kunert","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib50","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","article-title":"Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial","volume":"107","author":"Stevenson","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib51","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00003226-199311000-00008","article-title":"Effect of topical cyclosporin A on conjunctival T cells in patients with secondary Sjogren\u2019s syndrome","volume":"12","author":"Power","year":"1993","journal-title":"Cornea"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib52","first-page":"280","article-title":"A 0,05% cyclosporine treatment of the advanced dry eye syndrome","volume":"107","author":"Kujawa","year":"2005","journal-title":"Klin Oczna"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib53","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1185\/030079905X50615","article-title":"The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca","volume":"21","author":"Stonecipher","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib54","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.ophtha.2005.05.013","article-title":"Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years","volume":"112","author":"Barber","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib55","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2165\/00003088-200544030-00003","article-title":"Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye","volume":"44","author":"Tang-Liu","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib56","first-page":"90","article-title":"Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A","volume":"42","author":"Brignole","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib57","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/01.ico.0000133994.22392.47","article-title":"Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca","volume":"24","author":"Strong","year":"2005","journal-title":"Cornea"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib58","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ard.45.9.732","article-title":"Cyclosporin A (CyA) in primary Sjogren\u2019s syndrome: a double blind study","volume":"45","author":"Drosos","year":"1986","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib59","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/ard.46.2.89","article-title":"Effect of cyclosporin A (CyA) on the immunopathological lesion of the labial minor salivary glands from patients with Sjogren\u2019s syndrome","volume":"46","author":"Dalavanga","year":"1987","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib60","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1463-5224.2005.00390.x","article-title":"Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca","volume":"8","author":"Berdoulay","year":"2005","journal-title":"Vet Ophthalmol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib61","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0002-9394(02)01982-7","article-title":"Topical tacrolimus treatment of atopic eyelid disease","volume":"135","author":"Rikkers","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib62","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1463-5224.2005.04062.x","article-title":"The effect of topical pimecrolimus on keratoconjunctivitis sicca and chronic superficial keratitis in dogs: results from an exploratory study","volume":"8","author":"Nell","year":"2005","journal-title":"Vet Ophthalmol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib63","article-title":"Comparison of pimecrolimus 1%, 0.3% and 0.1% with vehicle for the treatment of dry eye in the controlled adverse environment (CAE) model","volume":"46","author":"Ousler","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib64","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0161-6420(99)90171-9","article-title":"Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome","volume":"106","author":"Marsh","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib65","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0002-9394(03)00326-X","article-title":"The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study","volume":"136","author":"Avunduk","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib66","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.0.CO;2-X","article-title":"Soft drug design: general principles and recent applications","volume":"20","author":"Bodor","year":"2000","journal-title":"Med Res Rev"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib67","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ajo.2004.04.052","article-title":"A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance","volume":"138","author":"Pflugfelder","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib68","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/archopht.1996.01100140141005","article-title":"Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids","volume":"114","author":"Leibowitz","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib69","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/sj.eye.6701537","article-title":"Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjogren\u2019s syndrome patients","volume":"19","author":"Aragona","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib70","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0960-0760(96)00190-2","article-title":"Androgen stimulation of lacrimal gland function in mouse models of Sjogren\u2019s syndrome","volume":"60","author":"Sullivan","year":"1997","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib71","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1210\/jcem-64-1-32","article-title":"Influence of testosterone therapy on clinical and immunological features of autoimmune diseases associated with Klinefelter\u2019s syndrome","volume":"64","author":"Bizzarro","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib72","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0378-5122(00)00181-X","article-title":"Treatment of keratoconjunctivitis sicca with topical androgen","volume":"37","author":"Worda","year":"2001","journal-title":"Maturitas"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib73","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.ajo.2004.11.042","article-title":"Combined esterified estrogen and methyltestosterone treatment for dry eye syndrome in postmenopausal women","volume":"139","author":"Scott","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib74","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-4615-5359-5_2","article-title":"Influence of gender, sex steroid hormones, and the hypothalamic-pituitary axis on the structure and function of the lacrimal gland","volume":"438","author":"Sullivan","year":"1998","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib75","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1749-6632.2002.tb04217.x","article-title":"Androgen deficiency, meibomian gland dysfunction, and evaporative dry eye","volume":"966","author":"Sullivan","year":"2002","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib76","first-page":"592","article-title":"Androgen influence on lacrimal gland apoptosis, necrosis, and lymphocytic infiltration","volume":"40","author":"Azzarolo","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib77","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/bjo.84.1.76","article-title":"Identification of androgen receptor protein and 5-alpha-reductase mRNA in human ocular tissues","volume":"84","author":"Rocha","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib78","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0378-5122(00)00181-X","article-title":"Treatment of keratoconjunctivitis sicca with topical androgen","volume":"37","author":"Worda","year":"2001","journal-title":"Maturitas"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib79","article-title":"Retrospective analysis of dry eye patients using 3% transdermal testosterone cream","volume":"45","author":"Connor","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib80","article-title":"No increase in IOP observed in patients using transdermal testosterone for three years","volume":"47","author":"Connor","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib81","first-page":"273","article-title":"Protocol for the clinical management of dry mouth","volume":"9","author":"Silvestre-Donat","year":"2004","journal-title":"Med Oral"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib82","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.tripleo.2003.07.010","article-title":"An update of the etiology and management of xerostomia","volume":"97","author":"Porter","year":"2004","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib83","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1089\/107555302320825174","article-title":"A third study on the use of orally administered anhydrous crystalline maltose for relief of dry mouth in primary Sjogren\u2019s syndrome","volume":"8","author":"Fox","year":"2002","journal-title":"J Altern Complement Med"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib84","first-page":"630","article-title":"Artificial saliva products and drugs to treat xerostomia","volume":"48","author":"Wynn","year":"2000","journal-title":"Gen Dent"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib85","first-page":"29","article-title":"Review of the use of polymers in saliva substitutes for symptomatic relief of xerostomia","volume":"17","author":"Urquhart","year":"2006","journal-title":"J Clin Dent"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib86","first-page":"262","article-title":"A new medication for treatment of dry mouth in Sjogren\u2019s syndrome","volume":"118","author":"Al-Hashimi","year":"2001","journal-title":"Tex Dent J"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib87","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1741-2358.1997.00054.x","article-title":"A preliminary assessment of intra-oral lubricating systems for dry mouth patients","volume":"14","author":"Frost","year":"1997","journal-title":"Gerodontology"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib88","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1600-0714.2005.00305.x","article-title":"Randomized-controlled trial: effect of a reservoir biteguard on quality of life in xerostomia","volume":"34","author":"Robinson","year":"2005","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib89","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/archinte.151.6.1149","article-title":"Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia)","volume":"151","author":"Fox","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib90","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/archinte.162.11.1293","article-title":"Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial","volume":"162","author":"Fife","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib91","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/rheumatology\/41.6.670","article-title":"Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sjogren\u2019s syndrome","volume":"41","author":"Rosas","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib92","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0929-6646(09)60266-7","article-title":"Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjogren\u2019s Syndrome in Taiwan","volume":"10","author":"Wu","year":"2006","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib93","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-006-0507-8","article-title":"Efficacy prediction of cevimeline in patients with Sjogren\u2019s syndrome","author":"Yamada","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib94","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/rheumatology\/32.1.52","article-title":"A preliminary study on the interferon-alpha treatment for xerostomia of Sjogren\u2019s syndrome","volume":"32","author":"Shiozawa","year":"1993","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib95","first-page":"367","article-title":"Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sjogren\u2019s syndrome patients","volume":"14","author":"Ferraccioli","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib96","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/jir.1998.18.255","article-title":"Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjogren\u2019s syndrome","volume":"18","author":"Shiozawa","year":"1998","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib97","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1089\/107999099313497","article-title":"Treatment of primary Sjogren\u2019s syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial","volume":"19","author":"Ship","year":"1999","journal-title":"J Interferon ytokine Res"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib98","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1067\/moe.2003.30","article-title":"A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjogren\u2019s syndrome","volume":"95","author":"Khurshudian","year":"2003","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib99","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/art.11199","article-title":"Treatment of primary Sjogren\u2019s syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results","volume":"49","author":"Cummins","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib100","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1089\/107999099313479","article-title":"Interferon-alpha upregulates gene expression of aquaporin-5 in human parotid glands","volume":"19","author":"Smith","year":"1999","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib101","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/art.20998","article-title":"Activation of the type I interferon system in primary Sjogren\u2019s syndrome: a possible etiopathogenic mechanism","volume":"52","author":"Bave","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib102","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/ncprheum0173","article-title":"Mechanisms of Disease: primary Sjogren\u2019s syndrome and the type I interferon system","volume":"2","author":"Nordmark","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib103","first-page":"149","article-title":"Prednisone and piroxicam for treatment of primary Sjogren\u2019s syndrome","volume":"11","author":"Fox","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib104","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2169\/internalmedicine.38.938","article-title":"Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjogren\u2019s syndrome","volume":"38","author":"Miyawaki","year":"1999","journal-title":"Intern Med"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard.2006.052647","article-title":"Progression of salivary gland dysfunction in patients with Sjogren\u2019s syndrome","volume":"66","author":"Pijpe","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib106","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/ard.57.8.464","article-title":"Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjogren\u2019s syndrome","volume":"57","author":"Izumi","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib107","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/ard.62.11.1038","article-title":"Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjogren\u2019s syndrome","volume":"62","author":"Kok","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib108","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1089\/104303403322542257","article-title":"Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjogren\u2019s syndrome","volume":"14","author":"Kok","year":"2003","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib109","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/ard.2005.038232","article-title":"Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren\u2019s syndrome","volume":"65","author":"Lodde","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib110","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1136\/ard.2006.052761","article-title":"Experience with experimental biological treatment and local gene therapy of Sjogren\u2019s syndrome: implications for exocrine pathogenesis and treatment","volume":"65","author":"Lodde","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib111","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1740-2557-2-6","article-title":"Expression of TNF inhibitor gene in the lacrimal gland promotes recovery of tear production and tear stability and reduced immunopathology in rabbits with induced autoimmune dacryoadenitis","volume":"2","author":"Trousdale","year":"2005","journal-title":"J Autoimmune Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib112","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/art.10315","volume":"46","author":"Azuma","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib113","first-page":"912","article-title":"Cepharanthin, a biscoclaurine alkaloid, prevents destruction of acinar tissues in murine Sjogren\u2019s syndrome","volume":"33","author":"Azuma","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib114","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/labinvest.3700234","article-title":"Expression of aquaporin-5 in and fluid secretion from immortalized human salivary gland ductal cells by treatment with 5-aza-2\u2032-deoxycytidine: a possibility for improvement of xerostomia in patients with Sjogren\u2019s syndrome","volume":"85","author":"Motegi","year":"2005","journal-title":"Lab Invest"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib115","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.critrevonc.2006.07.010","article-title":"Decitabine\u2014bedside to bench","volume":"61","author":"Oki","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib116","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/rheumatology\/keh714","article-title":"Primary Sjogren\u2019s syndrome: current and emergent aetiopathogenic concepts","volume":"44","author":"Ramos-Casals","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib117","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1002\/art.20472","article-title":"Effective treatment of a mouse model of Sjogren\u2019s syndrome with eyedrop administration of anti-CD4 monoclonal antibody","volume":"50","author":"Hayashi","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib118","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1002\/art.11352","article-title":"Development of autoimmune exocrinopathy resembling Sjogren\u2019s syndrome in adoptively transferred mice with autoreactive CD4+ T cells","volume":"48","author":"Arakaki","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib119","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/08916930400021352","article-title":"Non-depleting anti-CD4 antibody not only prevents onset but resolves sialadenitis in NOD mice","volume":"37","author":"Thompson","year":"2004","journal-title":"Autoimmunity"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib120","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.mlg.0000154726.77915.cc","article-title":"Tissue engineering of functional salivary gland tissue","volume":"115","author":"Joraku","year":"2005","journal-title":"Laryngoscope"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib121","doi-asserted-by":"crossref","DOI":"10.1089\/ten.2006.12.2939","article-title":"Re-engineering primary epithelial cells from rhesus monkey parotid glands for use in developing an artificial salivary gland","author":"Tran","year":"2006","journal-title":"Tissue Eng"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib122","article-title":"Tissue-engineered tear secretory system: functional lacrimal gland acinar cells cultured on matrix protein-coated substrata","author":"Selvam","year":"2006","journal-title":"J Biomed Mater Res B Appl Biomater"},{"issue":"2","key":"10.1016\/j.semarthrit.2007.06.002_bib123","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0161-6420(98)93406-6","article-title":"Transplantation of the autologous submandibular gland for most severe cases of keratoconjunctivitis sicca","volume":"105","author":"Geerling","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib124","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/ijom.2002.0438","article-title":"Microvascular autologous submandibular gland transfer in severe cases of keratoconjunctivitis sicca","volume":"33","author":"Yu","year":"2004","journal-title":"Oral Maxillofac Surg"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib125","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1590\/S0004-27492005000400012","article-title":"Transplantation of labial salivary glands for severe dry eye treatment","volume":"68","author":"Soares","year":"2005","journal-title":"Ar Qbras Oftalmol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib126","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/00029330-200603020-00009","article-title":"Establishment of submandibular gland allotransplantation model in miniature swine","volume":"119","author":"Ge","year":"2006","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib127","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.joms.2005.10.040","article-title":"Transplantation of vascularized submandibular gland in dogs","volume":"64","author":"Tanaka Isomura","year":"2006","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib128","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/ard.44.9.610","article-title":"Oesophageal dysfunction in patients with primary Sjogren\u2019s syndrome","volume":"44","author":"Tsianos","year":"1985","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib129","first-page":"358","article-title":"Alternate-day steroid therapy for patients with primary Sjogren\u2019s syndrome","volume":"15","author":"Tabbara","year":"1983","journal-title":"Ann Ophthalmol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib130","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/ard.60.5.511","article-title":"Reversibility of histological and immunohistological abnormalities in sublabial salivary gland biopsy specimens following treatment with corticosteroids in Sjogren\u2019s syndrome","volume":"60","author":"Zandbelt","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib131","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1177\/096120339300200103","article-title":"Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation","volume":"2","author":"Fox","year":"1993","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib132","first-page":"803","article-title":"Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells","volume":"20","author":"Sperber","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib133","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/rheumatology\/keh506","article-title":"Hydroxychloroquine therapy in patients with primary Sjogren\u2019s syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase","volume":"44","author":"Dawson","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib134","first-page":"1028","article-title":"Sjogren\u2019s syndrome: treatment with D-penicillamine and hydroxychloroquine","volume":"12","author":"Lakhanpal","year":"1985","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib135","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0002-9343(88)90365-8","article-title":"Treatment of primary Sjogren\u2019s syndrome with hydroxychloroquine","volume":"85","author":"Fox","year":"1988","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib136","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard.52.5.360","article-title":"Hydroxychloroquine treatment for primary Sjogren\u2019s syndrome: a two year double blind crossover trial","volume":"52","author":"Kruize","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib137","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1177\/096120339600500108","article-title":"Treatment of primary Sjogren\u2019s syndrome with hydroxychloroquine: a retrospective, open-label study","volume":"5","author":"Fox","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib138","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/ard.58.4.253","article-title":"Hydroxychloroquine treatment for primary Sjogren\u2019s syndrome: its effect on salivary and serum inflammatory markers","volume":"58","author":"Tishler","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib139","first-page":"555","article-title":"Methotrexate in primary Sjogren\u2019s syndrome","volume":"14","author":"Skopouli","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib140","first-page":"896","article-title":"A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren\u2019s syndrome","volume":"25","author":"Price","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib141","first-page":"53","article-title":"Assessment of sulphasalazine as a treatment modality in Sjogren\u2019s disease in NZB\/NZW F1 hybrid mice","volume":"14","author":"Yeoman","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib142","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/ard.50.9.645","article-title":"Meningitis associated with sulphasalazine in a patient with Sjogren\u2019s syndrome and polyarthritis","volume":"50","author":"Merrin","year":"1991","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib143","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/014107688007300114","article-title":"Sulphasalazine-induced systemic lupus erythematosus in a patient with Sjogren\u2019s syndrome","volume":"73","author":"Crisp","year":"1980","journal-title":"J R Soc Med"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib144","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00004836-199203000-00012","article-title":"Sulfasalazine-induced fulminant hepatic failure","volume":"14","author":"Marinos","year":"1992","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib145","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/pgmj.72.850.499","article-title":"Primary Sjogren\u2019s syndrome, ulcerative colitis and selective IgA deficiency","volume":"72","author":"Steuer","year":"1996","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib146","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2006.060905","article-title":"Safety and efficacy of Leflunomide in primary Sjogren\u2019s syndrome\u2014a phase II pilot study","author":"van Woerkom","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib147","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1089\/jop.2006.22.168","article-title":"Mycophenolate mofetil as an immunosuppressive agent in refractory inflammatory eye disease","volume":"22","author":"Choudhary","year":"2006","journal-title":"J Ocul Pharmacol Ther"},{"issue":"suppl 1","key":"10.1016\/j.semarthrit.2007.06.002_bib148","doi-asserted-by":"crossref","first-page":"s64","DOI":"10.1177\/096120330501400114","article-title":"Mycophenolate mofetil in patients with hepatitis C virus infection","volume":"14","author":"Ramos-Casals","year":"2005","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.semarthrit.2007.06.002_bib149","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0049-0172(98)80040-1","article-title":"Predictors of lymphoma development in primary Sjogren\u2019s syndrome","volume":"28","author":"Sutcliffe","year":"1998","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib150","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/art.1780390508","article-title":"Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren\u2019s syndrome","volume":"39","author":"Tzioufas","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib151","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/00003495-200464020-00001","article-title":"Myelopathy in Sjogren\u2019s syndrome: role of nonsteroidal immunosuppressants","volume":"64","author":"Rogers","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib152","first-page":"709","article-title":"Myelopathies secondary to Sjogren\u2019s syndrome: treatment with monthly intravenous cyclophosphamide associated with corticosteroids","volume":"33","author":"de Seze","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib153","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/archneur.63.11.1612","article-title":"Peripheral neuropathy in primary sjogren syndrome: a population-based study","volume":"63","author":"Goransson","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib154","first-page":"1552","article-title":"Pure sensory neuropathy in primary Sjogren\u2019s syndrome","volume":"30","author":"Font","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib155","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/jnnp.60.6.699","article-title":"Intravenous immunoglobulin therapy in sensory neuropathy associated with Sjogren\u2019s syndrome","volume":"60","author":"Molina","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib156","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1212\/WNL.51.2.650-b","article-title":"High-dose i.v. immunoglobulin for peripheral neuropathy associated with Sjogren\u2019s syndrome","volume":"51","author":"Pascual","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib157","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/jnnp.2005.084533","article-title":"Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjogren\u2019s syndrome","volume":"77","author":"Kizawa","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib158","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1212\/01.WNL.0000046680.47883.7D","article-title":"Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjogren\u2019s syndrome","volume":"60","author":"Takahashi","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib159","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1212\/WNL.61.6.873","article-title":"Benefit of IVIg for long-standing ataxic sensory neuronopathy with Sjogren\u2019s syndrome: comment","volume":"61","author":"Burns","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib160","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1212\/WNL.61.6.873","article-title":"Benefit of IVIg for long-standing ataxic sensory neuronopathy with Sjogren\u2019s syndrome","volume":"61","author":"Wolfe","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib161","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1002\/art.11343","article-title":"Antiidiotypic antibodies neutralize auto-antibodies that inhibit cholinergic neurotransmission","volume":"48","author":"Cavill","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib162","first-page":"839","article-title":"Polyneuropathy disclosing primary Gougerot-Sjogren syndrome","volume":"143","author":"Bakchine","year":"1987","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib163","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000052142","article-title":"Plasmapheresis in the treatment of ataxic sensory neuropathy associated with Sjogren\u2019s syndrome","volume":"45","author":"Chen","year":"2001","journal-title":"Eur Neurol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib164","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1212\/WNL.51.5.1451","article-title":"D-penicillamine treatment for chronic sensory ataxic neuropathy associated with Sjogren\u2019s syndrome","volume":"51","author":"Asahina","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib165","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/jnnp.2004.049502","article-title":"Interferon alfa treatment for Sjogren\u2019s syndrome associated neuropathy","volume":"76","author":"Yamada","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib166","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.59.7.1113","article-title":"Severe sensory neuronopathy responsive to infliximab in primary Sjogren\u2019s syndrome","volume":"59","author":"Caroyer","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib167","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/mus.20664","article-title":"Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial","volume":"35","author":"Gorson","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib168","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00005792-200007000-00005","article-title":"Clinically significant and biopsy-documented renal involvement in primary Sjogren syndrome","volume":"79","author":"Goules","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib169","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10067-005-1131-8","article-title":"Acute renal failure due to mesangial proliferative glomerulonephritis in a pregnant woman with primary Sjogren\u2019s syndrome","volume":"25","author":"Adam","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib170","first-page":"707","article-title":"Primary Sjogren\u2019s syndrome complicated with cryoglobulinemic glomerulonephritis, myocarditis, and multi-organ involvement","volume":"103","author":"Kau","year":"2004","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib171","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1093\/ndt\/13.10.2624","article-title":"Crescentic glomerulonephritis associated with membranous nephropathy in a case with primary Sjogren\u2019s syndrome","volume":"13","author":"Tatsumi","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib172","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2169\/internalmedicine.46.1835","article-title":"Membraneous glomerulonephritis and non-Hodgkin\u2019s lymphoma in a patient with primary Sjogren\u2019s syndrome","volume":"46","author":"Iwanaga","year":"2007","journal-title":"Intern Med"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib173","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/01.bor.0000198002.42826.c2","article-title":"Cryoglobulinemic vasculitis","volume":"18","author":"Ferri","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib174","first-page":"1032","article-title":"Dramatic response to intravenous high dose gamma-globulin in refractory vasculitis of the skin associated with Sjogren\u2019s syndrome","volume":"25","author":"Durez","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib175","first-page":"1102","article-title":"Intravenous gammaglobulin in the treatment of central nervous system vasculitis associated with Sjogren\u2019s syndrome","volume":"27","author":"Canhao","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib176","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1182\/blood-2002-09-2856","article-title":"Efficacy and safety of rituximab in type II mixed cryoglobulinemia","volume":"101","author":"Zaja","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib177","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","article-title":"Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases","volume":"64","author":"Gottenberg","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib178","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/rheumatology\/keh248","article-title":"Combined therapy with rituximab plus cyclophosphamide\/doxorubicin\/vincristine\/prednisone (CHOP) for Sjogren\u2019s syndrome-associated B-cell aggressive non-Hodgkin\u2019s lymphomas","volume":"43","author":"Voulgarelis","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib179","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/ard.2005.046193","article-title":"Long term remission of Sjogren\u2019s syndrome associated aggressive B cell non-Hodgkin\u2019s lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)","volume":"65","author":"Voulgarelis","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib180","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren\u2019s syndrome","volume":"66","author":"Seror","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib181","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/03009740500484056","article-title":"Successful treatment of Sjogren\u2019s syndrome with rituximab","volume":"35","author":"Touma","year":"2006","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib182","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/qjmed\/93.12.825","article-title":"Immune cytopenias as the presenting finding in primary Sjogren\u2019s syndrome","volume":"93","author":"Schattner","year":"2000","journal-title":"QJM"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib183","first-page":"482","article-title":"Autoimmune hemolytic anemia preceding Sjogren\u2019s syndrome","volume":"10","author":"Schattner","year":"1983","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib184","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/ard.62.5.476","article-title":"Primary Sjogren\u2019s syndrome associated agranulocytosis: a benign disorder?","volume":"62","author":"Coppo","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib185","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/sarh.2002.31547","article-title":"Agranulocytosis in Sjogren\u2019s syndrome: two case reports and analysis of 11 additional reported cases","volume":"31","author":"Friedman","year":"2002","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib186","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jca.10018","article-title":"Serum hyperviscosity syndrome responding to therapeutic plasmapheresis in a patient with primary Sjogren\u2019s syndrome","volume":"17","author":"Simon","year":"2002","journal-title":"J Clin Apher"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib187","first-page":"595","article-title":"[A case of Sjogren\u2019s syndrome associated with advanced hemolytic anemia caused by worsening autoimmune cholangiopathy]","volume":"38","author":"Yamanouchi","year":"1998","journal-title":"Ryumachi"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib188","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1445-5994.1998.tb02974.x","article-title":"Relapsing thrombotic thrombocytopenic purpura (TTP) in Sjogren\u2019s syndrome","volume":"28","author":"Campbell","year":"1998","journal-title":"Aust NZ J Med"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib189","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s100670200013","article-title":"Thrombotic thrombocytopenic purpura as an initial presentation of primary Sjogren\u2019s syndrome","volume":"21","author":"Schattner","year":"2002","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib190","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s10165-004-0287-4","article-title":"Thrombotic thrombocytopenic purpura complicating Sjogren\u2019s syndrome with crescentic glomerulonephritis and membranous nephritis","volume":"14","author":"Abe","year":"2004","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib191","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.4049\/jimmunol.152.11.5532","article-title":"Cytokine mRNA expression in salivary gland biopsies of Sjogren\u2019s syndrome","volume":"152","author":"Fox","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib192","first-page":"311","article-title":"Intrferon gamma and tumor necrosis factor alpha induce Fas expression and anti-Fas mediated apoptosis in a salivary ductal cell line","volume":"18","author":"Matsumura","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib193","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/1529-0131(200008)43:8<1756::AID-ANR12>3.0.CO;2-H","article-title":"Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production by the introduction of a super-repressor form of inhibitor of nuclear factor kappaBalpha complementary DNA into immortalized human salivary gland acinar cells","volume":"43","author":"Azuma","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib194","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/1529-0131(200110)44:10<2371::AID-ART401>3.0.CO;2-W","article-title":"Infliximab in patients with primary Sjogren\u2019s syndrome: a pilot study","volume":"44","author":"Steinfeld","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib195","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1002\/art.10674","article-title":"Infliximab in primary Sjogren\u2019s syndrome: one-year followup","volume":"46","author":"Steinfeld","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib196","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of iniximab in primary Sjogren\u2019s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren\u2019s Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib197","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sjogren\u2019s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib198","first-page":"96","article-title":"Etanercept in the treatment of patients with primary Sjogren\u2019s syndrome: a pilot study","volume":"31","author":"Zandbelt","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib199","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/ard.2005.038406","article-title":"Immunological consequences of thalidomide treatment in Sjogren\u2019s syndrome","volume":"65","author":"Moutsopoulos","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib200","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/art.20416","article-title":"Prominent adverse effects of thalidomide in primary Sjogren\u2019s syndrome","volume":"51","author":"Pillemer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib201","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/ard.2005.041186","article-title":"Lymphoma and other malignancies in primary Sjogren\u2019s syndrome: a cohort study on cancer incidence and lymphoma predictors","volume":"65","author":"Theander","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2007.06.002_bib202","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/art.20176","article-title":"Mortality and causes of death in primary Sjogren\u2019s syndrome: a prospective cohort study","volume":"50","author":"Theander","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib203","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.4065\/80.8.1087","article-title":"Non-Hodgkin lymphoma: diagnosis and treatment","volume":"80","author":"Ansell","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib204","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/art.10947","article-title":"Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy","volume":"48","author":"Silverman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib205","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/00003072-200202000-00019","article-title":"F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin\u2019s lymphoma of the parotid gland in a patient with Sjogren\u2019s syndrome: before and after anti-CD20 antibody rituximab therapy","volume":"27","author":"Shih","year":"2002","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib206","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/art.11109","article-title":"Improvement in Sjogren\u2019s syndrome following therapy with rituximab for marginal zone lymphoma","volume":"49","author":"Somer","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib207","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/rheumatology\/keh308","article-title":"Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren\u2019s syndrome","volume":"43","author":"Harner","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib208","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/ard.2004.030684","article-title":"Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren\u2019s syndrome and associated MALT lymphoma","volume":"64","author":"Pijpe","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib209","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sjogren\u2019s syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib210","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0952-7915(02)00356-4","article-title":"Humoral immunity and long-lived plasma cells","volume":"14","author":"Manz","year":"2002","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib211","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s10067-005-0086-0","article-title":"Successful treatment of a patient with primary Sjogren\u2019s syndrome with Rituximab","volume":"25","author":"Ring","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib212","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/art.11021","article-title":"Differential control of CD22 ligand expression on B and T lymphocytes, and enhanced expression in murine systemic lupus","volume":"48","author":"Lajaunias","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib213","first-page":"3982S","article-title":"Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties","volume":"9","author":"Carnahan","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib214","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2006.05.6291","article-title":"Phase II Multicenter Trial of Epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin\u2019s lymphoma","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib215","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1200\/JCO.2005.13.821","article-title":"Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin\u2019s lymphoma","volume":"23","author":"Leonard","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib216","doi-asserted-by":"crossref","first-page":"R74","DOI":"10.1186\/ar1942","article-title":"Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus","volume":"8","author":"Dorner","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib217","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/ar2018","article-title":"Epratuzumab (humanized anti-CD22 antibody) in primary Sjogren\u2019s syndrome: an open-label Phase I\/II study","volume":"8","author":"Steinfeld","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib218","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.molimm.2006.05.007","article-title":"Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab","volume":"44","author":"Carnahan","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib219","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/art.10434","article-title":"2-chloro-2\u2032-deoxyadenosine in the treatment of Sjogren\u2019s syndrome-associated B cell lymphoproliferation","volume":"46","author":"Voulgarelis","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.semarthrit.2007.06.002_bib220","first-page":"2413","article-title":"Are women with Sjogren\u2019s syndrome androgen-deficient?","volume":"30","author":"Sullivan","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib221","first-page":"1259","article-title":"Low serum dehydroepiandrosterone sulfate in women with primary Sjogren\u2019s syndrome as an isolated sign of impaired HPA axis function","volume":"28","author":"Valtysdottir","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib222","first-page":"1267","article-title":"Sex steroid hormones in primary Sjogren\u2019s syndrome","volume":"30","author":"Brennan","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib223","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/ard.62.9.875","article-title":"Mental wellbeing and quality of sexual life in women with primary Sjogren\u2019s syndrome are related to circulating dehydro-epiandrosterone sulphate","volume":"62","author":"Valtysdottir","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib224","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20540","article-title":"Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjogren\u2019s syndrome","volume":"51","author":"Pillemer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib225","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/art.21313","article-title":"Dehydroepiandrosterone versus placebo for Sjogren\u2019s syndrome: comment on the article by Pillemer et al","volume":"53","author":"van Vollenhoven","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib226","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-137-9-200211050-00031","article-title":"Octreotide therapy for the Sjogren syndrome","volume":"137","author":"Phan","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib227","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1530\/eje.0.143S021","article-title":"Somatostatin receptor subtypes in human immune cells","volume":"143","author":"Lichtenauer-Kaligis","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib228","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.dld.2003.11.020","article-title":"Somatostatin receptor distribution and function in immune system","volume":"36","author":"Ferone","year":"2004","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib229","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S0026-0495(96)90092-X","article-title":"Somatostatin receptor expression in clinical immunology","volume":"45","author":"van Hagen","year":"1996","journal-title":"Metabolism"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib230","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1093\/rheumatology\/38.9.814","article-title":"Zidovudine in primary Sjogren\u2019s syndrome","volume":"38","author":"Steinfeld","year":"1999","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib231","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/archneur.63.9.1318","article-title":"Combined antiviral-immunosuppressive treatment in human T-lymphotrophic virus 1-Sjogren-associated myelopathy","volume":"63","author":"Pot","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib232","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.amjmed.2005.09.015","article-title":"Primary Sjogren\u2019s syndrome and vitamin B12 deficiency: preliminary results in 80 patients","volume":"119","author":"Andres","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib233","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-3083.2005.01688.x","article-title":"The BAFF\/APRIL system in systemic autoimmune diseases with a special emphasis on Sjogren\u2019s syndrome","volume":"62","author":"Szodoray","year":"2005","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib234","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/01.bor.0000172801.56744.c3","article-title":"Immunopathogenesis of primary Sjogren\u2019s syndrome: implications for disease management and therapy","volume":"17","author":"Hansen","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib235","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1172\/JCI0214121","article-title":"Association of BAFF\/BLyS overexpression and altered B cell differentiation with Sjogren\u2019s syndrome","volume":"109","author":"Groom","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib236","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/ard.62.2.168","article-title":"The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren\u2019s syndrome","volume":"62","author":"Mariette","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib237","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s10875-004-6240-7","article-title":"Programmed cell death of peripheral blood B cells determined by laser scanning cytometry in Sjogren\u2019s syndrome with a special emphasis on BAFF","volume":"24","author":"Szodoray","year":"2004","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib238","article-title":"Increase of B-cell activating factor of the TNF family (BAFF) after rituximab: insights into a new regulating system of BAFF production","author":"Lavie","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib239","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/art.10734","article-title":"Increased salivary gland tissue expression of Fas","volume":"48","author":"Bolstad","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib240","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1002\/art.22004","article-title":"Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjogren\u2019s syndrome","volume":"54","author":"Downie-Doyle","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib241","first-page":"1370","article-title":"HLA-DQB1 CAR1\/CAR2","volume":"40","author":"Hadj Kacem","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib242","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-6143.2005.01158.x","article-title":"LFA-1 (CD11a) as a therapeutic target","volume":"6","author":"Nicolls","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib243","unstructured":"http:\/\/clinicaltrials.gov\/ct\/show\/NCT00344448 accessed February 27, 2007."},{"key":"10.1016\/j.semarthrit.2007.06.002_bib244","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1046\/j.1365-3083.1999.00533.x","article-title":"Increased frequency of cells secreting interleukin-6 and interleukin-10 in peripheral blood of patients with primary Sjogren\u2019s syndrome","volume":"49","author":"Halse","year":"1999","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib245","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s10238-004-0049-9","article-title":"Increased levels of interleukin-10 in saliva of Sjogren\u2019s syndrome patients","volume":"4","author":"Bertorello","year":"2004","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib246","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1167\/iovs.03-0755","article-title":"Prophylactic effect of IL-10 gene transfer on induced autoimmune dacryoadenitis","volume":"45","author":"Zhu","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib247","doi-asserted-by":"crossref","first-page":"R447","DOI":"10.1186\/ar1209","article-title":"Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjogren\u2019s syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate","volume":"6","author":"Bombardieri","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib248","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/ncprheum0173","article-title":"Mechanisms of disease: primary Sjogren\u2019s syndrome and the type I interferon system","volume":"2","author":"Nordmark","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib249","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/art.21745","article-title":"Antagonist of interferon-inducible protein 10\/CXCL10 ameliorates thprogression of autoimmune sialadenitis in MRL\/lpr mice","volume":"54","author":"Hasegawa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib250","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-3083.2005.01593.x","article-title":"Induction of oral tolerance in experimental Sjogren\u2019s syndrome autoimmunity","volume":"61","author":"Kurien","year":"2005","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.semarthrit.2007.06.002_bib251","doi-asserted-by":"crossref","first-page":"8409","DOI":"10.4049\/jimmunol.175.12.8409","article-title":"Immunization with short peptides from the 60-kDa Ro antigen recapitulates the serological and pathological findings as well as the salivary gland dysfunction of Sjogren\u2019s syndrome","volume":"175","author":"Scofield","year":"2005","journal-title":"J Immunol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017207001138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017207001138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T21:34:30Z","timestamp":1684013670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017207001138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":251,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S0049017207001138"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2007.06.002","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}